Siolta Therapeutics

Siolta Therapeutics, Inc.

is a clinical-stage biopharmaceutical company based in San Carlos, California, founded in 2016. The company specializes in developing live biotherapeutic products (LBPs) derived from the human microbiome, aiming to address chronic inflammatory diseases. Co-founded by Dr. Nikole Kimes and Dr. Susan Lynch, Siolta leverages their expertise in microbiology and immunology to create innovative microbiome-based therapies. The company's flagship offering is the Precision Symbiotics PlatformTM, which integrates clinical data, bioinformatics, and microbial science to engineer bacterial consortia targeting specific disease mechanisms. Siolta also maintains in-house Good Manufacturing Practice (GMP) facilities to ensure high-quality production of its microbial products. Its lead product, STMC-103H, is in Phase 2 clinical development for preventing atopic diseases in at-risk newborns, with a focus on conditions like atopic dermatitis, food allergies, and asthma. Siolta Therapeutics is committed to redefining treatment approaches by emphasizing prevention and restoration through microbiome health.